Arcellx, Inc. (ACLX)
65.20
+1.60
(+2.52%)
USD |
NASDAQ |
Dec 31, 16:00
65.29
+0.09
(+0.14%)
After-Hours: 20:00
Arcellx Free Cash Flow: -201.18M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Gilead Sciences, Inc. | 9.162B |
| Johnson & Johnson | 20.46B |
| Amicus Therapeutics, Inc. | 9.691M |
| Relmada Therapeutics, Inc. | -39.99M |
| Invivyd, Inc. | -80.44M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -49.21M |
| Cash from Investing (Quarterly) | -20.03M |
| Cash from Financing (Quarterly) | 86.10M |
| Free Cash Flow Per Share (Quarterly) | -0.8748 |
| Free Cash Flow to Equity (Quarterly) | -48.78M |
| Free Cash Flow to Firm (Quarterly) | -49.50M |
| Free Cash Flow Yield | -5.55% |